{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:30:09Z","timestamp":1787729409217,"version":"build-2784847793"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T00:00:00Z","timestamp":1332115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Fibrous dysplasia (FD) is a skeletal disease caused by somatic activating mutations of the cyclic adenosine monophosphate (cAMP)-regulating protein, \u03b1-subunit of the Gs stimulatory protein (Gs\u03b1). These mutations lead to replacement of normal bone by proliferative osteogenic precursors, resulting in deformity, fracture, and pain. Medical treatment has been ineffective in altering the disease course. Receptor activator of NF-\u03baB ligand (RANKL) is a cell-surface protein involved in many cellular processes, including osteoclastogenesis, and is reported to be overexpressed in FD-like bone cells. Denosumab is a humanized monoclonal antibody to RANKL approved for treatment of osteoporosis and prevention of skeletal-related events from bone metastases. We present the case of a 9-year-old boy with severe FD who was treated with denosumab for a rapidly expanding femoral lesion. Immunohistochemical staining on a pretreatment bone biopsy specimen revealed marked RANKL expression. He was started on monthly denosumab, with an initial starting dose of 1\u2009mg\/kg and planned 0.25\u2009mg\/kg dose escalations every 3 months. Over 7 months of treatment he showed marked reduction in pain, bone turnover markers (BTMs), and tumor growth rate. Denosumab did not appear to impair healing of a femoral fracture that occurred while on treatment. With initiation of treatment he developed hypophosphatemia and secondary hyperparathyroidism, necessitating supplementation with phosphorus, calcium, and calcitriol. BTMs showed rapid and sustained suppression. With discontinuation there was rapid and dramatic rebound of BTMs with cross-linked C-telopeptide (reflecting osteoclast activity) exceeding pretreatment levels, accompanied by severe hypercalcemia. In this child, denosumab lead to dramatic reduction of FD expansion and FD-related bone pain. Denosumab was associated with clinically significant disturbances of mineral metabolism both while on treatment and after discontinuation. Denosumab treatment of FD warrants further study to confirm efficacy and determine potential morbidity, as well as to determine the mechanism of RANKL in the pathogenesis of FD and related bone marrow stromal cell diseases. \u00a9 2012 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.1603","type":"journal-article","created":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T18:39:44Z","timestamp":1332182384000},"page":"1462-1470","source":"Crossref","is-referenced-by-count":231,"title":["Denosumab treatment for fibrous dysplasia"],"prefix":"10.1093","volume":"27","author":[{"given":"Alison M","family":"Boyce","sequence":"first","affiliation":[{"name":"National Institute of Child Health and Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA"},{"name":"Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch (CSDB), National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H","family":"Chong","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch (CSDB), National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Yao","sequence":"additional","affiliation":[{"name":"Radiology and Imaging Sciences, National Institutes of Health (NIH), Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel I","family":"Gafni","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch (CSDB), National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn H","family":"Kelly","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch (CSDB), National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E","family":"Chamberlain","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Institutes of Health (NIH), Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Bassim","sequence":"additional","affiliation":[{"name":"National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Cherman","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch (CSDB), National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Ellsworth","sequence":"additional","affiliation":[{"name":"University of Michigan Health Systems, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine Z","family":"Kasa-Vubu","sequence":"additional","affiliation":[{"name":"University of Michigan Health Systems, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A","family":"Farley","sequence":"additional","affiliation":[{"name":"University of Michigan Health Systems, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo A","family":"Molinolo","sequence":"additional","affiliation":[{"name":"Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisan","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch (CSDB), National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T","family":"Collins","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch (CSDB), National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,3,19]]},"reference":[{"key":"2024020318272638900_bib1","first-page":"415","volume-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","author":"Collins","year":"2006","edition":"6th ed"},{"key":"2024020318272638900_bib2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archsurg.1938.01190230153012","article-title":"Polyostotic fibrous dysplasia","volume":"36","author":"Lichtenstein","year":"1938","journal-title":"Arch Surg."},{"key":"2024020318272638900_bib3","first-page":"777","article-title":"Fibrous dysplasia of bone: a condition affecting one, several or many bones, the graver cases of which may present abnormal pigmentation of skin, premature sexual development, hyperthyroidism or still other extraskeletal abnormalities","volume":"33","author":"Lichtenstein","year":"1942","journal-title":"Arch Pathol."},{"key":"2024020318272638900_bib4","first-page":"743","article-title":"Osteitis fibrosa cystica; the case of a nine year old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism","volume":"52","author":"McCune","year":"1936","journal-title":"Am J Dis Child."},{"key":"2024020318272638900_bib5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM193704292161701","article-title":"Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females, report of five cases","volume":"216","author":"Albright","year":"1937","journal-title":"N Engl J Med."},{"key":"2024020318272638900_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-1172-3-12","article-title":"McCune-Albright syndrome","volume":"3","author":"Dumitrescu","year":"2008","journal-title":"Orphanet J Rare Dis."},{"issue":"5","key":"2024020318272638900_bib7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1359\/jbmr.2001.16.5.806","article-title":"Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia","volume":"16","author":"Collins","year":"2001","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2024020318272638900_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","article-title":"FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","journal-title":"J Clin Invest."},{"issue":"24","key":"2024020318272638900_bib9","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","article-title":"Activating mutations of the stimulatory G protein in the McCune-Albright syndrome","volume":"325","author":"Weinstein","year":"1991","journal-title":"N Engl J Med."},{"key":"2024020318272638900_bib10","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1073\/pnas.89.11.5152","article-title":"Identification of a mutation in the gene encoding the \u03b1 subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome","volume":"89","author":"Schwindinger","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"2024020318272638900_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1399-0004.1986.tb01261.x","article-title":"The McCune-Albright syndrome: a lethal gene surviving by mosaicism","volume":"29","author":"Happle","year":"1986","journal-title":"Clin Genet."},{"issue":"Suppl 2","key":"2024020318272638900_bib12","doi-asserted-by":"crossref","first-page":"P125","DOI":"10.1359\/jbmr.06s224","article-title":"Fibrous dysplasia as a stem cell disease","volume":"21","author":"Riminucci","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2024020318272638900_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1677\/JME-10-0097","article-title":"Skeletal progenitors and the GNAS gene: fibrous dysplasia of bone read through stem cells","volume":"45","author":"Riminucci","year":"2010","journal-title":"J Mol Endocrinol."},{"issue":"6","key":"2024020318272638900_bib14","first-page":"1587","article-title":"Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation","volume":"151","author":"Riminucci","year":"1997","journal-title":"Am J Pathol."},{"issue":"2","key":"2024020318272638900_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J","article-title":"The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks","volume":"187","author":"Riminucci","year":"1999","journal-title":"J Pathol."},{"issue":"8","key":"2024020318272638900_bib16","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1172\/JCI2361","article-title":"Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells","volume":"101","author":"Bianco","year":"1998","journal-title":"J Clin Invest."},{"issue":"5","key":"2024020318272638900_bib17","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1359\/jbmr.091036","article-title":"Transfer, analysis, and reversion of the fibrous dysplasia cellular phenotype in human skeletal progenitors","volume":"25","author":"Piersanti","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"Suppl 2","key":"2024020318272638900_bib18","doi-asserted-by":"crossref","first-page":"P105","DOI":"10.1359\/jbmr.06s220","article-title":"Surgery for fibrous dysplasia","volume":"21","author":"Stanton","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020318272638900_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1359\/JBMR.041111","article-title":"An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone","volume":"20","author":"Collins","year":"2005","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2024020318272638900_bib20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S8756-3282(03)00221-7","article-title":"Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia","volume":"33","author":"Parisi","year":"2003","journal-title":"Bone."},{"issue":"10","key":"2024020318272638900_bib21","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1210\/jc.2003-030050","article-title":"Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone","volume":"88","author":"Plotkin","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024020318272638900_bib22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.juro.2009.04.023","article-title":"Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial","volume":"182","author":"Fizazi","year":"2009","journal-title":"J Urol."},{"issue":"8","key":"2024020318272638900_bib23","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med."},{"issue":"7320","key":"2024020318272638900_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature."},{"issue":"7320","key":"2024020318272638900_bib25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature."},{"issue":"4","key":"2024020318272638900_bib26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/path.2567","article-title":"Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas","volume":"218","author":"Mikami","year":"2009","journal-title":"J Pathol."},{"issue":"3","key":"2024020318272638900_bib27","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1245\/s10434-006-9277-4","article-title":"Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis","volume":"14","author":"Sasaki","year":"2007","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"2024020318272638900_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","article-title":"RANK ligand as a therapeutic target for bone metastases and multiple myeloma","volume":"34","author":"Roodman","year":"2008","journal-title":"Cancer Treat Rev."},{"issue":"35","key":"2024020318272638900_bib29","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol."},{"issue":"9768","key":"2024020318272638900_bib30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet."},{"issue":"9","key":"2024020318272638900_bib31","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1172\/JCI42391","article-title":"Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice","volume":"120","author":"Molyneux","year":"2010","journal-title":"J Clin Invest."},{"issue":"3","key":"2024020318272638900_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol."},{"issue":"10","key":"2024020318272638900_bib33","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020318272638900_bib34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/BF00347333","article-title":"Case report 114","volume":"5","author":"Pelzmann","year":"1980","journal-title":"Skel Radiol."},{"issue":"9","key":"2024020318272638900_bib35","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/00000478-199309000-00009","article-title":"Massive chondroid differentiation in fibrous dysplasia of bone (fibrocartilaginous dysplasia)","volume":"17","author":"Ishida","year":"1993","journal-title":"Am J Surg Pathol."},{"issue":"1","key":"2024020318272638900_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00256-003-0718-x","article-title":"Fibrous dysplasia with cartilaginous differentiation (\u201cfibrocartilaginous dysplasia\u201d): a review, with an illustrative case followed for 18 years","volume":"33","author":"Kyriakos","year":"2004","journal-title":"Skel Radiol."},{"issue":"4","key":"2024020318272638900_bib37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"6717","key":"2024020318272638900_bib38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature."},{"key":"2024020318272638900_bib39"},{"issue":"1","key":"2024020318272638900_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1148\/radiology.184.1.1609087","article-title":"Epi- and metaphyseal changes in children caused by administration of bisphosphonates","volume":"184","author":"van Persijn van Meerten","year":"1992","journal-title":"Radiology."},{"issue":"7","key":"2024020318272638900_bib41","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1359\/JBMR.040303","article-title":"Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis","volume":"19","author":"Rauch","year":"2004","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020318272638900_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","article-title":"Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case\/case series studies","volume":"47","author":"Giusti","year":"2010","journal-title":"Bone."},{"issue":"2","key":"2024020318272638900_bib43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1359\/jbmr.081113","article-title":"Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing","volume":"24","author":"Gerstenfeld","year":"2009","journal-title":"J Bone Miner Res."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1603","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/27\/7\/1462\/56560567\/1603_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/27\/7\/1462\/56560567\/1603_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:46:25Z","timestamp":1710341185000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/27\/7\/1462-1470\/7598305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,19]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,3,19]]},"published-print":{"date-parts":[[2012,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1603","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,7,1]]},"published":{"date-parts":[[2012,3,19]]}}}